Sufficient Clinical Effect for Weight Reduction, Diabetic Control and MASLD by Weekly Tirzepatide (Mounjaro)

Shinohara Y, Yamashita H, Matsuzaki S, Tanizaki M, Kato Y and Bando H

Published on: 2026-05-20

Abstract

The patient is a 33-year-old male with type 2 diabetes (T2D), hyperuricemia, dyslipidemia and fatty liver (MASLD). His stature showed 183 cm, 127.6 kg, and BMI 38.1 kg/m². Pulse wave velocity (PWV) revealed ankle-brachial index (ABI) 1.26/1.14, and brachial ankle PWV (baPWV) 1185/1181. His medication regimen consisted of Metformin, Canagliflozin, Rosuvastatin, and Febuxostat. From July 2025, tirzepatide (Mounjaro) from 2.5mg to 7.5mg was initiated. HbA1c decreased significantly from 6.8% to 5.9% with weight reduction from 134 kg to 125 kg in 8 months, respectively. Furthermore, improvements of blood chemistry were observed for AST, ALT, GGT, ChE, and LDL levels.?